Journals / Joint diseases and related surgery / 2021 / Cilt: 32 - Sayı: 3

Effects of palliative radiotherapy and bisphosphonate usageon bone turnover marker levels in cancer patients withosteolytic bone metastases

Pages
705–712
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, in this study, there were nostatistically significant differences between the levels of markers fortwo different RT schedules.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: In this study, we aimed to investigate the bone turnovermarker levels according to bisphosphonate usage and radiotherapy(RT) in cancer patients with metastases in osteolytic pattern.
📊
Key Findings & Data:Patients and methods: A total of 52 patients (13 males, 39 females;median age: 52 years; range, 37 to 78 years) treated with RT forosteolytic bone metastases between April 2005 and April 2006were retrospectively analyzed.
💡
Conclusion & Impact:However, in this study, there were nostatistically significant differences between the levels of markers fortwo different RT schedules.
🔬Design:Research Article
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: In this study, we aimed to investigate the bone turnovermarker levels according to bisphosphonate usage and radiotherapy(RT) in cancer patients with metastases in osteolytic pattern. Patients and methods: A total of 52 patients (13 males, 39 females;median age: 52 years; range, 37 to 78 years) treated with RT forosteolytic bone metastases between April 2005 and April 2006were retrospectively analyzed. Bone-specific alkaline phosphatase(BAP), amino-terminal cross-linked telopeptide of type I collagen(NTX-I), amino-terminal propeptide of type I procollagen (PINP),osteocalcin (OC), deoxypyridinoline (DPD), pyridinoline (PYD),alkaline phosphatase (ALP), creatinine, calcium (Ca), phosphate (P),magnesium (Mg), and 24-h urine Ca levels were measured in blood andurine before the initiation of RT, six weeks and six months after RT. Results: A decrease in BAP, PINP, and creatinine levels wasobserved after RT (Week 6 p=0.006, Month 6 p=0.008). Sixteenpatients who already used bisphosphonate before RT were excludedfrom statistical calculation. The remaining 36 patients who weretreated with bisphosphonate after the first blood test were evaluatedseparately. In this group of patients, BAP, PINP, NTX, creatinine, andCa levels significantly increased at six weeks after RT. The PINP andcreatinine values significantly decreased at six months after RT. Thevariation between two different RT arms was assessed with repeatedmeasures variance analysis. There was a statistically significantdifference for NTX, OC, and creatinine levels between the first andsecond measurements. Conclusion: Radiotherapy is an effective method in the treatmentof osteolytic bone metastases. Bone turnover markers can providean objective evaluation on RT response and parallel to imagingmodalities criteria for evaluation. Bisphosphonates may alter thelevels of these indicators. However, in this study, there were nostatistically significant differences between the levels of markers fortwo different RT schedules.

🔖

Cite This Article

AKMANSU, M., GÖKSEL, F., ŞENTÜRK, E., DEMİRCİOĞLU, F. (2022). Effects of palliative radiotherapy and bisphosphonate usageon bone turnover marker levels in cancer patients withosteolytic bone metastases. Joint diseases and related surgery, Cilt: 32 - Sayı: 3, 705–712. https://ajindex.com/articles/559232

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76
  2. Cecchini MG, Wetterwald A, van der Pluijm G, Thalmann GN. Molecular and biological mechanisms of bone metastasis. EAU Update Series 2005;3:214-26
  3. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6
  4. Al Husaini H, Wheatley-Price P, Clemons M, Shepherd FA. Prevention and management of bone metastases in lung cancer: A review. J Thorac Oncol 2009;4:251-9
  5. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64
  6. Atik OŞ, Sezgin EA, Tepedelenlioğlu HE. The role of biomarkers in osteoarthritis and osteoporosis for early diagnosis and monitoring prognosis. Eklem Hastalik Cerrahisi 2019;30:175-6
  7. Seibel MJ. Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol 2005;2:504-17
  8. Ferreira A, Alho I, Casimiro S, Costa L. Bone remodeling markers and bone metastases: From cancer research to clinical implications. Bonekey Rep 2015;4:668
  9. Swaminathan R. Biochemical markers of bone turnover. Clin Chim Acta 2001;313:95-105
  10. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002;42:1228-36
  11. Vinholes JJ, Purohit OP, Abbey ME, Eastell R, Coleman RE. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 1997;8:1243-50
  12. Wang R, Zhang S, Jiang Z, Tian J, Wang T, Song S. Bone metabolism markers: Indicators of loading dose intravenous ibandronate treatment for bone metastases from breast cancer. Clin Exp Pharmacol Physiol 2017;44:88-93
  13. Lipton A, Demers L, Curley E, Chinchilli V, Gaydos L, Hortobagyi G, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998;34:2021-6
  14. Berruti A, Dogliotti L, Gorzegno G, Torta M, Tampellini M, Tucci M, et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 1999;45:1240-7
  15. Body JJ, Dumon JC, Gineyts E, Delmas PD. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer 1997;75:408-12
  16. Wada N, Fujisaki M, Ishii S,